ホーム
探索
nav.journalClub
トレンド
その他
synapse
⌘+K
言語
日本語
日本語
A Cohort Comparison of CXCR4 Antagonists for Multiple Myeloma Mobilization | Synapse
March 3, 2026
A Cohort Comparison of CXCR4 Antagonists for Multiple Myeloma Mobilization
PA
Peter Abdelmessieh
Fox Chase Cancer Center
YS
Yuliya Shestovska
Fox Chase Cancer Center
DS
Daniel Stapor
Fox Chase Cancer Center
See all
Key Points
CXCR4 antagonists successfully enhance mobilization of stem cells in multiple myeloma patients, showing promise for treatment efficacy.
The study observed improved mobilization metrics for CXCR4 antagonists, indicating a significant difference in outcomes.
Cohort comparison design enabled a thorough assessment of different CXCR4 antagonists in a clinical setting.
Further investigation is needed to explore the long-term benefits of these mobilization strategies in multiple myeloma management.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Abdelmessieh et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7603cc6e9836116a2cc69
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.320